Transgene Biotek Share Price
Small Cap | Pharmaceuticals and health care | BSE: 526139
₹4.23 
-0.04 (-0.94 %)
Last Updated: 25 Feb 2025 12:00 AM
BEARISH
Overview
Open (₹) 4.44
High (₹) 4.44
Low (₹) 4.10
Prev. Close (₹) 4.27
Volume 31,189
VWAP (₹) 4.15
ROCE (%) -0.40
Industry P/E 43.77
TTM P/E -141.00
P/B Ratio 3.00
Market Cap (₹) Cr.32.05
Dividend Yield (%)--
EPS (₹) -0.09
ROE-6.38%
Sales Growth (%) 326.43
Profit Growth (%)-89.09
Day Range
4.444.44
52 Week Range
3.8711.34
Historical Returns
Returns (6M)
-51.27 %
Returns (1Y)
-60.17 %
Returns (3Y)
24.41 %
Returns (5Y)
29.75 %
Returns (6M)
-51.27 %
Returns (1Y)
-60.17 %
Returns (3Y)
24.41 %
Returns (5Y)
29.75 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Growth in Net Profit Margin (QoQ)
- Growth in Annual Net Profit with increasing Profit Margin (YoY)
- Increasing Revenue every Quarter for the past 4 Quarters
Technicals
Technical Rating
BEARISHRSI 42.56
MFI 43.11
ATR 0.33
Commodity Channel Index -67.19
ROC125 -51.66
ROC21 -6.83
Williams %R -56.63
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 4.42 | 4.60 | 4.76 | 4.26 | 4.08 | 3.92 | 3.74 |
| Week Ago | 4.17 | 4.29 | 4.38 | 4.08 | 3.96 | 3.87 | 3.75 |
| Month Ago | 4.76 | 4.97 | 5.10 | 4.63 | 4.42 | 4.29 | 4.08 |
EMA & SMA
4.23
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 4.25
9 Day 4.25
10 Day 4.29
12 Day 4.35
14 Day 4.35
20 Day 4.44
26 Day 4.47
50 Day 5.26
100 Day 6.17
200 Day 7.21
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| GEETANJALI INVESTMENTS | bulk | Sell | 01 Dec, 2023 | ₹8.16 | 8,96,281 | BSE |
| SAHASRAR CAPITAL PRIVATE LIMITED | bulk | Buy | 01 Dec, 2023 | ₹7.83 | 3,71,570 | BSE |
| MAYUR VIJAY PATWA | bulk | Buy | 01 Dec, 2023 | ₹8.19 | 4,01,000 | BSE |
| GEETANJALI INVESTMENTS | bulk | Sell | 24 Nov, 2023 | ₹9.10 | 7,16,159 | BSE |
| SAHASRAR CAPITAL PRIVATE LIMITED | bulk | Buy | 24 Nov, 2023 | ₹9.12 | 3,50,000 | BSE |
| GEETANJALI INVESTMENTS | bulk | Sell | 23 Nov, 2023 | ₹8.70 | 4,47,728 | BSE |
Insider Trading
Corporate Actions
No corporate actions available.
Announcements
| Date | Source | Detail |
|---|---|---|
| 14 Feb, 2025 | BSE India | Integrated Filing (Financial) |
| 24 Jan, 2025 | BSE India | Financial Results 31-12-2024. |
| 24 Jan, 2025 | BSE India | This has reference to our letter dated January 16 2025.\r\n\r\n1) The Board has considered and approved the unaudited Consolidated & Standalone Financial Results of the company, for the Quarter ended 31.12.2024 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015.\r\n\r\n2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2024 has also been approved.\r\n\r\n3) The Board has discussed and approved a funding proposal to raise funds on a\r\nsecuritized basis to address the pressing demands on the company and passed\r\nappropriate resolution to move the proposal forward.\r\n\r\nThe meeting commenced at 11:00 a.m. and concluded at 12:25 p.m. |
| 20 Jan, 2025 | BSE India | Statement of Deviation & Variation |
| 20 Jan, 2025 | BSE India | Compliances Certificate under Reg. 74(5) of SEBI |
| 16 Jan, 2025 | BSE India | TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve 1. To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended December 31, 2024.Along with (Standalone &\r\nConsolidated) Limited review report thereon.\r\n\r\n2. To transact such other business as may be required. |
| 31 Dec, 2024 | BSE India | order |
| 06 Dec, 2024 | BSE India | Outcome of Voting of 34th AGM held on 05th December, 2024. At 10:00 AM. |
| 05 Dec, 2024 | BSE India | Proceedings of the 34th AGM. |
| 13 Nov, 2024 | BSE India | Revised Results |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 20 Jan, 2025 | 24 Jan, 2025 |
| Quarterly Results & A.G.M. | -- | 05 Nov, 2024 | 12 Nov, 2024 |
| Quarterly Results | -- | 22 Jul, 2024 | 10 Aug, 2024 |
| Audited Results | -- | 14 May, 2024 | 30 May, 2024 |
| Quarterly Results | -- | 30 Jan, 2024 | 14 Feb, 2024 |
| Quarterly Results & Others | -- | 07 Nov, 2023 | 14 Nov, 2023 |
| Quarterly Results & Others | -- | 18 Jul, 2023 | 05 Aug, 2023 |
| Audited Results | -- | 15 May, 2023 | 30 May, 2023 |
| Quarterly Results | -- | 30 Jan, 2023 | 14 Feb, 2023 |
| Quarterly Results | -- | 07 Nov, 2022 | 12 Nov, 2022 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Transgene Biotek
Transgene Biotek is a Public Limited Listed company incorporated on 01/03/1990 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1990PLC011065 and registration number is 011065. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 0.23 Cr. and Equity Capital is Rs. 75.77 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1990
Managing Director
Dr. K Koteswara Rao
NSE Symbol
--
Transgene Biotek Management
| Name | Designation |
|---|---|
| Dr. K Koteswara Rao | Chairman & Managing Director |
| Mrs. Sujana Kadiam | Director |
| Mrs. Swetha Marri | Director |
| Mr. Santosh Kumar | Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,613.60  ₹1,639.50(-1.58%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,726.40  ₹5,702.55(0.42%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,463.35 ₹1,476.75(-0.91%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,342.10 ₹2,298.80(1.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,128.15 ₹1,164.55(-3.13%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Transgene Biotek
What is the share price of Transgene Biotek?
The share price of Transgene Biotek on 25 Feb, 2025 is ₹ 4.23.
What is 52W high and 52W low share price of Transgene Biotek?
The highest and lowest 52W share prices of Transgene Biotek are ₹ 12.460 and ₹ 5.790
What is the market cap of Transgene Biotek?
The market capitalization of Transgene Biotek as of 25 Feb, 2025 is ₹ 32.05 Crores
What is the P/E ratio of Transgene Biotek?
The current P/E ratio of Transgene Biotek as of 25 Feb, 2025 is 43.77
What is the PB ratio of Transgene Biotek?
The PB ratio of Transgene Biotek as of 25 Feb, 2025 is 3.00
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)